Supporting our findings, Nikolai et al. demonstrated that CDK4/6 inhibitors could inhibit proliferation in HER2-overexpressing BC cells by modulating E2F1 and its target genes, which are involved in HER2-driven DNA metabolism [33]. The gene discussed is ERBB2; the disease is breast cancer.